Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11164941 | 0.79 | HTT (0.47) | HPGDSEGLN2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL24003951 | 0.79 | ABCG2 (0.42) | RAF1HPGDSALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25583782 | 0.79 | HPGDS (0.40) | HPGDSEGLN2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2204306 | 0.79 | HPGDS (0.60) | HPGDSALDH1A1CYP1A2CYP3A4CLK4 | |
| SCHEMBL2633153 | 0.76 | CYP1A2 (0.53) | CYP1A2KDM4E | |
| SCHEMBL30666632 | 0.76 | CYP1A2 (0.53) | CYP1A2KDM4E | |
| SCHEMBL981901 | 0.74 | CDK8 (0.51) | EGLN2ALDH1A1CYP1A2CYP3A4CLK4 | |
| SCHEMBL17309719 | 0.73 | CYP1A2 (0.39) | ALDH1A1CYP1A2HSD17B10TSHRKDM4E | |
| SCHEMBL18378968 | 0.73 | CYP1A2 (0.39) | CYP1A2KDM4E | |
| SCHEMBL21064338 | 0.73 | CYP1A2 (0.39) | ALDH1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| CN-116783165-A | 1,2,3, 4-tetrahydroquinoline derivatives as YAP/TAZ-TEAD activation inhibitors for the treatment of cancer | 天主教鲁汶大学 | 2023-09-19 | — | — | CN | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
| CN-101223143-A | 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | RAF1 782/4885HPGDS 350/4885EGLN2 903/4885 |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | RAF1 187/4885HPGDS 2224/4885EGLN2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.